Prasinezumab
Parkinson’s Disease
Phase 2bActive (Partnered with Roche)
Key Facts
About Prothena
Prothena is a publicly traded biotech firm with a scientific legacy tracing back to Athena Neurosciences (founded 1986), focusing on the biology of misfolded proteins. It has built a diverse pipeline of investigational therapies, including partnered programs with Roche (prasinezumab for Parkinson's) and Bristol Myers Squibb (PRX005). The company's strategy integrates internal discovery with strategic collaborations to advance transformative medicines for devastating neurological and amyloid disorders.
View full company profile